NasdaqGS - Nasdaq Real Time Price USD

Prelude Therapeutics Incorporated (PRLD)

4.1750 +0.0350 (+0.85%)

As of 10:02:43 AM EDT. Market Open.

Trade PRLD on Coinbase

Chart Range Bar

Advanced Chart

AlphaSpace Chart

Loading chart for PRLD

Previous Close 4.1400
Open 4.1600
Bid 2.9800 x 200
Ask 5.3700 x 200
Day's Range 4.1150 - 4.2237
52 Week Range 1.1730 - 6.8300
Volume 15,376
Avg. Volume 496,548
Market Cap (intraday) 333.18M
Beta (5Y Monthly) 0.96
PE Ratio (TTM) --
EPS (TTM) -0.7300
Earnings Date (est.) Nov 11, 2026
Forward Dividend & Yield -- (0.00%)
1y Target Est 9.20
Zacks Rating Bullish

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

preludetx.com

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Trailing total returns as of 10/29/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

PRLD

43.97%

S&P 500 (^GSPC)

12.75%

1-Year Return

PRLD

164.24%

S&P 500 (^GSPC)

12.02%

3-Year Return

PRLD

130.66%

S&P 500 (^GSPC)

87.46%

5-Year Return

PRLD

76.25%

S&P 500 (^GSPC)

67.60%

Earnings Per Share

gaap GAAP

nongaap Normalized

gaap GAAP

nongaap Normalized

Revenue vs. Earnings

yearly Annual

quarterly Quarterly

yearly Annual

quarterly Quarterly

Q2 FY26

Revenue 5.7M

Earnings -13.92M

Profit Margin -244.06%

FY25

FY26

-15M

-10M

-5M

-300.0%

-280.0%

-260.0%

-240.0%

Analyst Price Targets

6.00

9.20 Average

4.1750 Current

12.00 High

Analyst Recommendations

Strong Buy
Buy
Hold
Underperform
Sell

Latest Rating

Date 9/17/2026

Analyst JP Morgan

Rating Action Initiated

Rating Overweight

Price Action Announces

Price Target 12

Valuation Measures

  
  
 Annual 

Market Cap
Enterprise Value
Trailing P/E
Forward P/E
PEG Ratio (current)
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue
Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

Profit Margin

-269.75%
Return on Assets (ttm)

-27.15%
Return on Equity (ttm)

-57.73%
Revenue (ttm)

22.42M
Net Income Avi to Common (ttm)

-60.49M
Diluted EPS (ttm)

-0.7300

Balance Sheet and Cash Flow

Total Cash (mrq)

151.76M
Total Debt/Equity (mrq)

13.20%
Levered Free Cash Flow (ttm)

-13.84M

PMVP PMV Pharmaceuticals, Inc.

1.3600 -1.45%

STTK Shattuck Labs, Inc.

5.90 +1.64%

FHTX Foghorn Therapeutics Inc.

2.1400 +0.47%

CCCC C4 Therapeutics, Inc.

3.4150 +0.59%

KYMR Kymera Therapeutics, Inc.

127.10 +3.75%

U.S. markets close in 5h 55m

Prelude Therapeutics Incorporated (PRLD)

Trading disclosure

15.97%

5.43%

-2.22%

43.97%

164.24%

-76.25%

-83.45%

Prelude Therapeutics Incorporated Overview Biotechnology / Healthcare

Full Time Employees

Fiscal Year Ends

Sector

Industry

Recent News

Performance Overview

YTD Return

1-Year Return

3-Year Return

5-Year Return

Earnings Trends

Earnings Per Share

Revenue vs. Earnings

Analyst Insights

Analyst Price Targets

Analyst Recommendations

Latest Rating

Statistics

Valuation Measures

Financial Highlights

Profitability and Income Statement

Balance Sheet and Cash Flow

Company Insights

Research Reports

People Also Watch